What to Know in Four Points
Sources: the Mounjaro® and Zepbound® prescribing information, both revised 08/2026.
The Stomach Takes Most of the Hit
Stomach side effects were reported by 37% to 44% of adults with type 2 diabetes on Mounjaro® and by 56% of adults on Zepbound® in its weight trials. Placebo rates were 20% and 30%, so the trials and populations differ, but the pattern is the same.
Step-Ups Are the Peak Period
Both labels say most nausea, vomiting and diarrhea happened during dose escalation and decreased over time, so some people notice the first weeks after a new dose more than the rest. Your prescriber can tell you what to expect at each step.
Most People Stayed on Treatment
Between 3.0% and 6.6% of people on Mounjaro® and between 1.9% and 4.3% on Zepbound® stopped because of stomach effects. Placebo rates were 0.4% and 0.5%.
Mounjaro® vs Zepbound®: Trial Rates Side by Side
Each range runs across the doses studied on that label, next to the placebo rate from the same trials. Mounjaro®'s Table 1 lists effects reported by at least 5% of people; Zepbound®'s lists effects reported by at least 2%, so some rows appear only in the label text or not at all. Rates from different trials cannot be directly compared.
| Side effect | Mounjaro® | Mounjaro® placebo | Zepbound® | Zepbound® placebo |
|---|---|---|---|---|
| Nausea | 12% to 18% | 4% | 25% to 29% | 8% |
| Diarrhea | 12% to 17% | 9% | 19% to 23% | 8% |
| Vomiting | 5% to 9% | 2% | 8% to 13% | 2% |
| Constipation | 6% to 7% | 1% | 11% to 17% | 5% |
| Indigestion | 5% to 8% | 3% | 9% to 10% | 4% |
| Stomach pain | 5% to 6% | 4% | 9% to 10% | 5% |
| Decreased appetite | 5% to 11% | 1% | Not in table | Not in table |
| Injection site reactions | 3.2% (label text) | 0.4% | 6% to 8% | 2% |
| Burping | 2.5% to 3.3% (label text) | 0.4% | 4% to 5% | 1% |
| Fatigue | Not in table | Not in table | 5% to 7% | 3% |
| Hair loss | Postmarketing reports only | No rate | 4% to 5% | 1% |
| Dizziness | Not in table | Not in table | 4% to 5% | 2% |
| Any stomach effect | 37% to 44% | 20% | 56% | 30% |
| Stopped for stomach effects | 3.0% to 6.6% | 0.4% | 1.9% to 4.3% | 0.5% |
Nausea
Nausea was reported by 12% to 18% of adults on Mounjaro® versus 4% on placebo. On Zepbound®, it was reported by 25% to 29% versus 8% on placebo.
Diarrhea and Vomiting
Diarrhea was reported by 12% to 17% on Mounjaro® and 19% to 23% on Zepbound®. Vomiting was reported by 5% to 9% on Mounjaro® and 8% to 13% on Zepbound®.
Constipation and Indigestion
Constipation was reported by 6% to 7% on Mounjaro® and 11% to 17% on Zepbound®. Indigestion was reported by 5% to 8% and 9% to 10%, respectively.
Effects in Only One Table
Decreased appetite appears in the Mounjaro® table at 5% to 11%. The Zepbound® table, which uses a lower 2% cut-off, adds injection site reactions, fatigue, hair loss, dizziness and burping, each above placebo. The Mounjaro® label reports injection site reactions (3.2%) and burping (2.5% to 3.3%) in its text instead, and lists hair loss only among postmarketing reports.
Why the Numbers Differ
The Mounjaro® trials enrolled adults with type 2 diabetes, while the Zepbound® trials enrolled adults with obesity or overweight. The labels say rates from different trials cannot be directly compared, so treat this table as context rather than a ranking.
When to Call Your Prescriber or 911
Swelling of the face, lips, tongue or throat, trouble breathing, fainting, or severe stomach pain that does not go away need emergency help, and severe or persistent vomiting, diarrhea or nausea, signs of dehydration or low blood sugar are reasons to contact your prescriber. Also call your prescriber right away about signs of gallbladder problems: pain in your upper stomach, fever, yellowing of your skin or eyes, or clay-colored stools. Each brand's full list is in Mounjaro® side effects and Zepbound® side effects.
This is not a complete list and it is not medical advice: if something feels wrong, call.
How Tirzepatide Works and Why It Upsets the Stomach
Every point here comes from the labels.
It Acts on Two Hormone Receptors
The labels describe tirzepatide as acting on both the GIP and GLP-1 receptors. That dual action is what sets it apart from semaglutide, which acts on GLP-1 receptors only.
Slower Digestion
Both labels state that tirzepatide delays gastric emptying. Food that stays in the stomach longer is linked with fullness, nausea and indigestion.
Each Dose Lasts Most of a Week
The labels give an elimination half-life of about 5 days, and about 5 to 6 days in people with obesity. Because each weekly dose lasts for days, some people notice their symptoms follow a weekly pattern. The tirzepatide half-life calculator shows what that looks like.
Brand-Specific Guides
For the full diabetes trial data, read Mounjaro® side effects. For the weight management and sleep apnea data, read Zepbound® side effects.
From the makers of this guide
Keep Track of Your Own Pattern
Pep AI lets you rate symptoms such as nausea, constipation, headache, fatigue and injection-site pain for severity each day, from a built-in list of GLP-1 symptoms grouped by body area, plus your own. A daily check-in records mood, energy and sleep quality as well. On the Dose tab, your side-effect trend sits next to your estimated level chart and above your dose history, so you can compare them.
- 01
Rate Symptoms by Severity
Pick from the built-in list or add your own, and rate how strong each one was that day.
- 02
Side-effect trend on the Dose tab
Your symptom trend over recent days, on the same tab as your Mounjaro® or Zepbound® doses.
- 03
Estimated level chart
An estimate from your logged doses and the label half-life, not a lab value.
Bring a Clear Record to Each Appointment
Pep AI exports a PDF report of your full history, including your doses and weight. A few seconds a day keeps your log complete, so the report is current when the next visit comes. For the symptoms worth raising with your prescriber, see Mounjaro® side effects or Zepbound® side effects.
Key takeaways
- Stomach side effects were reported by 37% to 44% of adults on Mounjaro® and 56% on Zepbound®, versus 20% and 30% on placebo.
- Both labels say most nausea, vomiting and diarrhea happened during dose escalation and decreased over time.
- 3.0% to 6.6% stopped Mounjaro® and 1.9% to 4.3% stopped Zepbound® because of stomach effects, versus 0.4% and 0.5% on placebo.
- Both labels carry the boxed thyroid C-cell tumor warning; the brand guides hold the full warnings and call lists.
- The two labels' trials enrolled different people, so their rates cannot be directly compared.
Bring your own pattern, not just the label's.
Pep AI logs your Mounjaro® or Zepbound® shots, symptoms with severity, meals and weight, and makes a PDF of your doses, injection sites and weight. Download Pep AI on iPhone or Android.
Frequently asked questions
Keep reading
Sources
This page summarizes the Mounjaro® and Zepbound® (both revised 08/2026) prescribing information for tirzepatide. It is general information, not medical advice, and does not replace your prescriber or pharmacist. Rates from different trials cannot be directly compared. Pep AI is not affiliated with or endorsed by Eli Lilly and Company. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026